After decades of decline, the number of Americans dying from cardiovascular disease has been rising steadily in recent years. Cardiovascular disease, sometimes referred to as heart disease, is a group of conditions that involve the heart and blood vessels. Common complications include heart attack, stroke and death.
Lives claimed by cardiovascular disease in the United States: 1920 - 20171
Reducing cardiovascular disease impact is an urgent national need2-4
NEARLY HALF of all US adults have some type of cardiovascular disease.
1 IN EVERY 4 deaths is related to cardiovascular disease each year in the United States.
Certain communities, for instance, Black Americans are 30% MORE LIKELY to die of cardiovascular disease than others.
|Source: American Heart Association, 2019||Source: Centers for Disease Control and Prevention, 2020||Source: Graham, 2015|
To address these alarming trends, new and transformative approaches are needed to proactively predict, prevent and better treat heart disease. At Novartis, we are collaborating on innovative population health approaches that go beyond medicines to reduce heart disease and its impact—equitably and at scale.
Our vision is to contribute to meaningful, enduring change for generations to come and be a trusted partner in the communities we serve. We believe that by combining knowledge and resources, we can reduce the burden of heart disease and address healthcare disparities for underserved populations and ensure that all patients – regardless of ethnicity, socioeconomic status, gender or geography – receive the care they need.
Learn more about how we are collaborating to reimagine and improve cardiovascular patient care, by exploring, introducing and championing innovative population health solutions:
- New initiative to help people with high cholesterol and associated cardiovascular disease
- New CardioHealth Alliance Established to Expedite Evidence-Based Solutions for Prevention and Care of Cardiovascular, Renal and Metabolic Diseases
- Jefferson Announces Collaboration to Address Cardiovascular Health Disparities in Philadelphia - Jefferson University Hospitals
- 2021 Xcenda Policy Paper: Undervaluing Diagnosis and Treatment of Atherosclerotic Cardiovascular Disease (ASCVD)